Press Releases

SneakPeek Snap: A Painless Microneedle-Based Push-Button Device for Early Fetal Sex Determination

The advancement of prenatal DNA technology and growing demand for early fetal sex determination have created a need for a simple and easy-to-use blood collection device that eliminates the pain and difficulty individuals encounter when utilizing traditional methods of blood collection such as venipuncture or lancet fingerstick. In this study, Gateway Genomics, the leading provider of fetal sex testing, introduces “SneakPeek Snap”, a novel microneedle-based, self-administered blood collection device that simplifies at-home blood collection for fetal sex testing.

read more

Gateway Genomics Ranks No. 56 in the Inc. 5000 Series: California’s Fastest-Growing Private Companies for 2021

For the second straight year, Gateway Genomics ranks as one of the top private companies in the Health sector, which includes biotech, pharmaceutical firms, and makers of medical devise and products for the health care market.

Gateway Genomics, a leading developer of direct-to-consumer genetic tests that give families insight into their future children, was recognized in this year’s Inc. 5000’s California list for the second year in a row, emerging as the 56th fastest-growing private company in the state, and #6 in the Health sector. Last year the company was included in the 2020 annual Inc. 5000 list of fastest-growing private companies in the United States.

read more

Gateway Genomics Surpasses 1000 Clinical Locations Across the US, UK, and Canada

Attracted by the ability to acquire new clients/patients early in pregnancy, provider signup for the SneakPeek Gender DNA Test climbed in 2020 and Q1 2021

Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, achieved a milestone of over 1,000 distributors of its SneakPeek Clinical test across the US, UK, and Canada. This number represents a doubling of locations since this time last year.

read more

Landmark Large-scale Publication Shows SneakPeek Early Gender DNA Test Predicts Fetal Sex with 99.9% Accuracy, Months Before Ultrasound

In one of the largest clinical studies of its kind, Gateway Genomics' SneakPeek test predicted gender accurately for 1028 of 1029 women between 7-37 weeks into pregnancy.

Gateway Genomics, leading provider of direct-to-consumer genetic tests focused on prenatal and pediatric information, announces a new publication titled, “Large scale follow-up research study: SneakPeek® Early Gender DNA Test 99.9% accurate for fetal sex by live-birth confirmation” in the International Journal of Pregnancy & Child Birth.

read more

Large scale follow-up research study: SneakPeek®Early Gender DNA Test 99.9% accurate for fetal sex by live-birth confirmation

Early fetal sex determination has become more prevalent among parents interested in planning for their unborn child. Current advances in non-invasive prenatal testing (NIPT) have facilitated this desire with safe and efficient methods such as the SneakPeek® Early Gender DNA Test (“SneakPeek”). Here, we report the accuracy of SneakPeek® from a large-scale clinical study of 1,029 pregnant women between 7 and 37 weeks of gestation (median =10 weeks).

read more

Gateway Genomics Launches SneakPeek Early Traits DNA Test that Uses Genetics to Provide a Child’s Features

With this new product, the company that’s known for the SneakPeek Early Gender DNA Test provides a window into what a child will look like as an adult, predicted nutrition levels, and sleep behavior, as predicted by genetics.

Gateway Genomics, leading provider of direct-to-consumer genetic tests focused on prenatal and pediatric information, launches the SneakPeek Early Traits DNA Test for parents of young children to learn more about their unique child. The test offers fun insights on adult physical features as well as helpful tips and advice for predicted nutrition levels and sleep behavior as gleaned from the child’s DNA.

read more

Gateway Genomics Surpasses 300,000 SneakPeek Early Gender DNA Tests Sold with Accelerating Sales in both At-Home and Clinical Channels

The sales milestone was achieved last month as online awareness of the product grew expansively and clinical providers reached nearly 1,000 locations.

Gateway Genomics, a leading developer of direct-to-consumer genetic tests that give families insight into their future children, announces inclusion in the Inc. 5000 2020 list of fastest growing private companies for the second year in a row. To qualify, companies must have been founded and generating revenue by March 31, 2016. Ranking in the list is determined by the percentage revenue growth from 2016 to 2019, with minimums set for each year. With 1,623% revenue growth from 2016 to 2019, Gateway Genomics ranked #296 in the list, and #22 in the Health sector.

read more

Motivations behind Early Fetal Sex Determination

There are many momentous events that accompany the journey of childbirth, one of which is the discovery of the fetus’s sex. What most expecting families are unaware of is that in addition to the traditional approaches, there exists newer developed technologies that allow for an earlier determination of the fetus’s sex. This maybe in part due to little research being conducted on reasons why expecting mothers opt for an earlier identification technique.

read more

Gateway Genomics Ranks 296 in the Inc. 5000 Fastest-Growing Private Companies in America List for 2020

For the second straight year, Gateway Genomics ranks in the top 25 private companies in the Health sector, which includes biotech, pharmaceutical firms, and makers of medical devices and products for the health care market.

Gateway Genomics, a leading developer of direct-to-consumer genetic tests that give families insight into their future children, announces inclusion in the Inc. 5000 2020 list of fastest growing private companies for the second year in a row. To qualify, companies must have been founded and generating revenue by March 31, 2016. Ranking in the list is determined by the percentage revenue growth from 2016 to 2019, with minimums set for each year. With 1,623% revenue growth from 2016 to 2019, Gateway Genomics ranked #296 in the list, and #22 in the Health sector.

read more

Gateway Genomics Announces Top 7 Reasons Why Women Want to Know Their Baby’s Gender Early

In a new study with over 1,000 participants across the US, UK, and Canada, “satisfying curiosity” was the #1 reason for fetal sex determination at 8 weeks into pregnancy.

Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, announces a new publication titled, “Reported Benefits of Early Fetal Sex Determination” in the International Journal of Pregnancy & Child Birth. In the study, over 1,000 postpartum moms who had taken the SneakPeek Early Gender DNA Test responded to a survey to share what benefits they received from knowing the gender of their babies early in pregnancy.

read more